Clinical Characteristics and Healthcare Resource Utilization for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review
**Background:** Mucopolysaccharidosis II (MPS II; Hunter syndrome) is a rare, X-linked, life-limiting lysosomal storage disease characterized by a deficiency in the activity of the enzyme iduronate-2-sulfatase. Accumulation of glycosaminoglycans in tissues and organs throughout the body causes cellu...
Main Authors: | Olulade Ayodele, Kersten Müller, Solmaz Setayeshgar, David Alexanderian, Karen S. Yee |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2022-05-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/jheor.2022.33801 |
Similar Items
-
P012: Measuring non-reducing terminal glycosaminoglycan fragments increases specificity and differentiates mucopolysaccharidosis type I (MPS I) from mucopolysaccharidosis type II (MPS II)
by: Taraka Donti, et al.
Published: (2023-01-01) -
P132: Clinical characteristics and management of patients with mucopolysaccharidosis II (MPS II) in the United States from the Hunter Outcome Survey*
by: Barbara Burton, et al.
Published: (2023-01-01) -
Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatment
by: Karen S. Yee, et al.
Published: (2024-04-01) -
Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II
by: Karen S. Yee, et al.
Published: (2024-03-01) -
Differences in MPS I and MPS II Disease Manifestations
by: Christiane S. Hampe, et al.
Published: (2021-07-01)